Septerna Inc

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco.

Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases

Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

A couple of analysts initiated coverage on Septerna, Inc. SEPN, which debuted on NASDAQ last month.

Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, today announced the closing of its upsized initial public offering (IPO) of 18,400,000 shares of its common stock at a public offering price of $18.00 per share, which includes an additional 2,400,000 shares issued upon the full exercise by the underwriters of their option to purchase additional shares. All of the shares were offered by Septerna.

Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering

Aldel Financial II Inc

Ingram Micro Holding

Li Bang International Corp Inc

VanEck

High Roller Technologies Inc

SAG Holdings Ltd

Synergy CHC Corp

Translational Development Acquisition Corp

Three sizable IPOs priced this past week, joined by a flurry of small issuers and blank check companies - Ingram Micro, Septerna, and WeRide. Several small issuers also listed this past week, including Synergy CHC, High Roller Technologies, SAG Holdings, and Li Bang. Two IPOs are tentatively scheduled to list in the week ahead, although some small issuers may join the calendar throughout the week - Peak Resources and Jinxin Technology.

U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names

Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of $970 million.

Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, today announced the pricing of its upsized initial public offering of 16,000,000 shares of its common stock at a public offering price of $18.00 per share. In addition, Septerna has granted the underwriters a 30-day option to purchase up to an additional 2,400,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Septerna, and the common stock is expected to begin trading on the Nasdaq Global Market on October 25, 2024, under the ticker symbol “SEPN.”

Septerna Prices Upsized Initial Public Offering

Goldman Sachs-backed drug developer Septerna said on Thursday it was seeking a valuation of $743.1 million in its upsized initial public offering in the United States.

Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO

Biotechnology company Septerna said on Monday it is aiming to raise up to $186 million in its initial public offering in the United States.

Biotech Septerna aims to raise up to $186 million in US IPO

Septerna, Inc. aims to raise $100 million in an IPO to advance its clinical-stage biopharma treatments for endocrine diseases, with SEP-786 in Phase 1 trials. The hypoparathyroidism treatment market is expected to grow at a robust CAGR of 6.9% from 2024 to 2032, driven by increased diagnoses and treatments. The firm is backed by top-tier life science investors and is well-capitalized but faces typical biopharma risks, including future financing needs and potential trial failures.

Septerna Pursues $100 Million IPO For Endocrine And Metabolic Drug Pipeline

News for Septerna Inc Stock (SEPN)